

First Report of Vancomycin Intermediate Staphylococcus aureus in infected Subclavian Stent

Ali Sabateen^{2*}, Hammam Rjoup², Tahreer Taha², Rami Zgari², Sari Abu Hania², Randa Kattan¹, Caroline Hajal², Ghada Safi², Ashraf Hussein² and Musa Hindiyeh^{1,2,3}

¹Caritas Baby Hospital, Bethlehem, Palestine

²Augusta Victoria Hospital, Jerusalem, Palestine

³Bethlehem University, Bethlehem, Palestine

⁴Palestine Central Laboratories, Ramallah, Palestine

*Corresponding author

Dr. Ali Sabateen, Infectious disease Department, Augusta Victoria Hospital Jerusalem, Palestine

Submitted: 19 May 2021; Accepted: 24 May 2021; Published: 01 Jun 2021

Citation: Ali Sabateen, Hammam Rjoup, Tahreer Taha, Rami Zgari, Sari Abu Hania, et al. (2021) First Report of Vancomycin Intermediate Staphylococcus aureus in infected Subclavian Stent. Journal of Clinical Review & Case Reports, 6(6):647-649.

Abstract

We report the presentation and management of a patient that developed vancomycin intermediate Staphylococcus aureus while on vancomycin therapy. Positron Emission Tomography Computed Tomography Scanning showed increased uptake in the left proximal subclavian stent compatible with the origin of the bacteremia.

Keywords: Vancomycin Intermediate Staphylococcus Aureus, PET/CT, Subclavian

Health care providers are continuously challenged with the emergence of antibiotic resistant bacteria. This exerts tremendous pressure on the infection control unit to prevent the spread of such resistant organisms in the healthcare setting. One of the important emerging pathogens is vancomycin intermediate Staphylococcus aureus (VISA) [1, 2]. Management of VISA infected patients is extremely problematic and may be difficult to eradicate, especially for patients with infected devices or foreign bodies [1, 3-5].

Worldwide, the first report of S. aureus with decreased susceptibility to vancomycin was described in Japan in 1997 [6]. Since then, several countries have reported the detection of VISA [7-11]. Fundamental characteristics of the VISA phenotype includes increased cell wall thickness, caused by differentially regulated cell wall biosynthesis and stimulatory pathway. On the molecular level, it is not well understood what contributes to the VISA phenotype.

Patients at high risk to develop infections due to VISA characteristically have prolonged hospitalization, persistent infections due to a poorly managed infected source, prolonged vancomycin treatment and MRSA treatment failure. What complicates patient management is the narrow range of active antibiotics against VISA. In general, invasive VISA infections are treated with distamycin and linezolid, two antimicrobial agents that are not readily available in developing countries [1, 12].

Here we report the first isolation of VISA in the blood culture of a hospitalized dialysis patient at Augusta Victoria Hospital, East Jerusalem and Palestine.

Case Study

An 80 year old male patient was admitted to the Augusta Victoria Hospital on June 4th 2013 to the Skilled Nursing Facility for long term health care. The patient's past medical history includes ischemic heart disease, status post coronary artery bypass graft (CABG) in 2010, chronic kidney disease on regular hemodialysis (three times weekly through arterial fistula), diabetes mellitus types II and hyperlipidemia, prostate hypertrophy and chronic obstructive pulmonary disease (COPD).

On November 23rd 2017, the patient developed hypotension and disorientation during his hemodialysis session without any other complaints. Detailed physical examination did not reveal an obvious source of infection, and hypoglycemia was ruled out. His laboratory workup results were as follows, C-reactive protein 39 mg/L, creatinine 3 mg/dL, Blood Urea Nitrogen (BUN) 42 mg/dL, aspartate amino transferase (AST) 29 U/L, alanine amino transferase (GPT) 6 U/L and alkaline phosphatase 73 U/L. The patient's complete blood count (CBC) showed leukocytosis 12x10³/uL of which 94% were neutrophils. One set of aerobic and anaerobic blood cultures, aerobic and anaerobic bottles, were collected from the patient's peripheral blood and incubated in the

Versa TREK® instrument (Thermo Fisher, USA). The patient was started empirically on vancomycin 750 mg and gentamicin 80 mg after each hemodialysis session. Subsequent antibiotic doses were adjusted according to the therapeutic antibiotic levels.

Blood cultures were inoculated on the appropriate culture medium according to the American Society of Microbiology Clinical Microbiology Manual [13]. All bottles grew Gram positive bacteria in clusters that were both 3% catalase and coagulase positive. Confirmation that the isolate was *S. aureus* was done on the Vitek® 2 instrument (bioMérieux, France).

Antibiotic susceptibility testing (AST) was performed according to the Clinical and Laboratory Standards Institute (CLSI) using Kirby Bauer disk diffusion and the E-test (bioMérieux, France) to determine the minimum inhibitory concentration (MIC). AST revealed that the *Staphylococcus aureus* isolate was methicillin-resistant (MRSA) based on the ceftiofloxacin disk screen [14]. It was susceptible to gentamicin, tetracycline, linezolid, rifampin and co-trimoxazole, and resistant to ciprofloxacin, erythromycin, clindamycin and levofloxacin. The vancomycin MIC by E-test was 1.0 µg/mL.

The patient underwent workup for his MRSA bacteremia. Detailed physical examination did not reveal signs of endocarditis, osteomyelitis, infected fistula or soft tissue infections. Transthoracic echocardiogram (TTE) did not show signs of endocarditis. Rheumatoid factor (RF) was negative. Vancomycin treatment was continued for 2 weeks while keeping the trough level between 15 and 20 µg/mL, and gentamicin was stopped after 3 days of therapy. Follow up peripheral blood cultures after 3 and 9 days of antibiotic treatment were negative. The patient's medical condition improved during therapy and he returned back to his base line.

On December 28th, 3 weeks after stopping vancomycin therapy, the patient developed fever (38.7°C), without chills, and no other symptoms. A septic workup was performed which included CBC and drawing two peripheral sets of blood cultures one each arm. The CBC showed WBC $7.3 \times 10^3 / \mu\text{l}$, with 62% neutrophils; both blood culture bottles grew MRSA. The vancomycin MIC by E-Test increased to 2 µg/mL. The patient was started on vancomycin 750mg and gentamicin 80mg after each hemodialysis session with close vancomycin trough level monitoring around 20 mg/dL. Extensive workup to find the source of the MRSA infection included Tran's esophageal echocardiography (TEE), whole body computerized tomography (CT) scan and RF did not indicate the source of infection. The patient was treated for 6 weeks and all follow up blood cultures during therapy were negative. During therapy the patient felt well with no complaints and returned back to his base line.

On 16th of February, 6 days after stopping the vancomycin treatment the patient developed hypotension with blood pressure 75/50 without fever or chills, and again with no obvious source of infection. Two sets of peripheral blood cultures were collected which grew MRSA with vancomycin MIC 2 µg/mL. The patient was started on distamycin 6mg/kg after each hemodialysis session, with adding cefazolin 1g once daily [14]. While the patient was on distamycin, a repeated two sets of blood culture on February

21st grew *S. aureus* with vancomycin MIC by E-test of 4 µg/mL. Per CLSI guidelines the *S. aureus* is now considered a VISA [13].

The patient underwent Positron Emission Tomography Computed Tomography (PET/CT) Scanning to complete the workup and to determine the possible source of the VISA infection. On March 2018, the PET/CT scan showed increase uptake in the left proximal subclavian area, identifying the presence of a stent in the artery, compatible with the source of the bacteremia (Figure 1 A: colored image and B: Black and white).



A



B

Figure 1 A: Colored positron Emission Tomography Computed Tomography (PET/CT) Scanning image showing increased uptake in the left proximal subclavian stent compatible with origin of bacteremia. B: Black and white PET/CT image

The presence of the stent was unexpected, and undocumented in the patient's medical records at Augusta Victoria Hospital. Follow up to ascertain the stents presence failed to reveal any new information when re-interviewing the family and the patient. Upon tracing the patient medical records to the referring hospital, a 2012 admission revealed documentation that the patient had a history of a subclavian artery stent insertion performed due to stenosis at a third hospital.

The patient was continued on distamycin with high dose of 8 mg/kg in combination with cefazolin 1 gram daily and was referred to a vascular surgeon for possible removal of the stent. At the time of writing this manuscript, the patient was free of relapse for 2 months.

Molecular characterization of the MRSA isolates revealed that the

MRSA isolate contained the hospital acquired SCCmec Type II cassette and was negative for the PVL gene and was not MRSA USA300 or USA400 strains by PCR [15].

Infection control measures included placing the patient with the VISA in a single room under strict contact isolation; hand hygiene adherence was strictly monitored daily. To assess if the bacteria had spread in the department, nasal swabs were collected from all the patients (N=21) in the unit and sent to the laboratory for *S. aureus* detections. Of the 21 patients 9 had MRSA in the nasal cavity, 4 MRSA strains had vancomycin MIC of 2 and 5 patients had MRSA with vancomycin MIC less or equal to 1. The patient with the MRSA bacteremia was negative for MRSA in the nasal cavity. In order to prevent the spread of the bacteria in the hospital, MRSA nasal decolonization with mupirocin ointment, twice daily for 5 days was initiated in addition to 4% chlorhexidine bathing, twice weekly. All patients tested negative for MRSA after the decolonizing step.

Our case emphasizes the importance of finding the source of the infection as prolonged vancomycin therapy can lead to the emergence of VISA. PET/CT scan was very instrumental in determining the source of the patient's bacteremia.

References

1. Balkhair A, Al Muharrmi Z, Darwish L, Farhan H, Sallam M () Treatment of vancomycin-intermediate *Staphylococcus aureus* (VISA) endocarditis with linezolid. *International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases* 2010; 14 Suppl 3: e227-9.
2. Conly JM, Johnston BL (2002) VISA, hetero-VISA and VRSA: the end of the vancomycin era? *The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses* 13: 282-284.
3. Werth BJ, Jain R, Hahn A (2018) Emergence of dalbavancin non-susceptible, vancomycin-intermediate *Staphylococcus aureus* (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen. *Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases* 24: 429 e1- e5.
4. Lai CC, Chen CC, Chuang YC, Tang HJ (2017) Combination of cephalosporins with vancomycin or teicoplanin enhances antibacterial effect of glycopeptides against heterogeneous vancomycin-intermediate *Staphylococcus aureus* (hVISA) and VISA. *Scientific reports* 7: 41758.
5. Saravolatz LD, Pawlak J, Johnson LB, Saravolatz LD, 2nd, Husain N (2010) In vitro activity of ceftobiprole against methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-intermediate *S. aureus* (VISA), vancomycin-resistant *S. aureus* (VRSA) and daptomycin-non-susceptible *S. aureus* (DNSSA). *International journal of antimicrobial agents* 36: 478-480.
6. Miller NC, Rudoy RC (2000) Vancomycin intermediate-resistant *Staphylococcus aureus* (VISA). *Orthopedic nursing* 19: 45-8; quiz 9-51.
7. Marques JB, Dalmolin TV, Bonez PC, Agertt VA, de Campos MM, et al. (2013) Detection of *Staphylococcus aureus* with an intermediate profile to vancomycin (VISA) isolate from Santa Maria, RS. *Brazilian journal of microbiology: [publication of the Brazilian Society for Microbiology]* 44: 277-279.
8. Chaiwongkarjohn S, Pramyothin P, Suwantarant N (2011) A report on the first case of vancomycin-intermediate *Staphylococcus aureus* (VISA) in Hawai'i. *Hawaii medical journal* 70: 233-236.
9. Gardete S, Aires-De-Sousa M, Faustino A, Ludovice AM, de Lencastre H (2008) Identification of the first vancomycin intermediate-resistant *Staphylococcus aureus* (VISA) isolate from a hospital in Portugal. *Microbial drug resistance* 14: 1-6.
10. Sng LH, Koh TH, Wang GC, Hsu LY, Kapi M, et al. (2005) Heterogeneous vancomycin-resistant *Staphylococcus aureus* (hetero-VISA) in Singapore. *International journal of antimicrobial agents* 25: 177-179.
11. Cosgrove SE, Carroll KC, Perl TM (2004) *Staphylococcus aureus* with reduced susceptibility to vancomycin. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America* 39: 539-545.
12. Kelley PG, Gao W, Ward PB, Howden BP (2011) Daptomycin non-susceptibility in vancomycin-intermediate *Staphylococcus aureus* (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. *The Journal of antimicrobial chemotherapy* 66: 1057-1060.
13. ASM (2016) *Clinical Microbiology Procedures Handbook*. In: Leber AL. *Aerobic Bacteriology*. USA: ASM Press.
14. Smith JR, Arya A, Yim J (2016) Daptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible *Staphylococcus aureus* in an In Vitro, Hollow-Fiber Model. *Antimicrobial agents and chemotherapy* 60: 3970-3975.
15. Zhang K, McClure JA, Elsayed S, Louie T, Conly JM (2008) Novel multiplex PCR assay for simultaneous identification of community-associated methicillin-resistant *Staphylococcus aureus* strains USA300 and USA400 and detection of *mecA* and Pantone-Valentine leukocidin genes, with discrimination of *Staphylococcus aureus* from coagulase-negative staphylococci. *Journal of clinical microbiology* 46: 1118-1122.

Copyright: ©2021 Dr. Ali Sabateen, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.